Genetic Instability and Intratumoral Heterogeneity in Neuroblastoma with MYCN Amplification Plus 11q Deletion

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Villamón, Eva ^a   Berbegall, Ana P ^a   Piqueras, Marta ^a   Tadeo, Irene ^b   Castel, Victoria ^c   Djos, Anna ^d   Martinsson, Tommy ^d   Navarro, Samuel ^a   Noguera, Rosa ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC MARKER; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MYCN GENE; NEUROBLASTOMA; ONSET AGE; OVERALL SURVIVAL; PRESCHOOL CHILD; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE;

CHILD; CHILD, PRESCHOOL; CHROMOSOME BREAKPOINTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; FEMALE; GENE AMPLIFICATION; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; MALE; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84872337690     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053740     Document Type: Article

References (51)

1. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, et al. (2009) Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 27: 1026-1033.
2. Coco S, Theissen J, Scaruffi P, Stigliani S, Moretti S, et al. (2012) Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma. Int J Cancer 131: 1591-1600.
3. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, et al. (2012) Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483: 589-593.
4. Stigliani S, Coco S, Moretti S, Oberthuer A, Fischer M, et al. (2012) High genomic instability predicts survival in metastatic high-risk neuroblastoma. Neoplasia 14: 823-832.
5. Morales La Madrid A, Nall MB, Ouyang K, Minor A, Raca G, et al. (2012) Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression. Pediatr Blood Cancer.
6. Brodeur GM, (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
7. Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, et al. (2011) Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer 105: 1940-1948.
8. Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, et al. (2011) A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma. Clin Cancer Res 17: 792-804.
9. Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner JT, et al. (2009) Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet 41: 718-723.
10. Maris JM, (2010) Recent advances in neuroblastoma. N Engl J Med 362: 2202-2211.
11. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, et al. (2010) Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol 28: 3122-3130.
12. Noguera R, Canete A, Pellin A, Ruiz A, Tasso M, et al. (2003) MYCN gain and MYCN amplification in a stage 4S neuroblastoma. Cancer Genet Cytogenet 140: 157-161.
13. Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, et al. (2009) International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 100: 1471-1482.
14. Ambros PF, Ambros IM, (2001) Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37: 492-504.
15. Theissen J, Boensch M, Spitz R, Betts D, Stegmaier S, et al. (2009) Heterogeneity of the MYCN oncogene in neuroblastoma. Clin Cancer Res 15: 2085-2090.
16. Kerbl R, Ambros IM, Ambros PF, Lackner H, Dornbusch HJ, et al. (2002) Neuroblastoma with focal MYCN amplification and bone marrow infiltration: a staging and treatment dilemma. Med Pediatr Oncol 38: 109-111.
17. Ando K, Ohira M, Ozaki T, Nakagawa A, Akazawa K, et al. (2008) Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation. Int J Cancer 123: 2087-2094.
18. Michels E, Hoebeeck J, De Preter K, Schramm A, Brichard B, et al. (2008) CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23. BMC Cancer 8: 173.
19. Caren H, Kryh H, Nethander M, Sjoberg RM, Trager C, et al. (2010) High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A 107: 4323-4328.
20. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, et al. (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27: 289-297.
21. Fischer M, Bauer T, Oberthur A, Hero B, Theissen J, et al. (2010) Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene 29: 865-875.
22. Spitz R, Hero B, Simon T, Berthold F, (2006) Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res 12: 3368-3373.
23. Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, et al. (2001) International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 92: 2451-2461.
24. Ambros IM, Benard J, Boavida M, Bown N, Caron H, et al. (2003) Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 21: 2077-2084.
25. Piqueras M, Navarro S, Canete A, Castel V, Noguera R, (2011) How to minimise the effect of tumour cell content in detection of aberrant genetic markers in neuroblastoma. Br J Cancer 105: 89-92.
26. Melegh Z, Csernak E, Toth E, Veleczki Z, Magyarosy E, et al. (2005) DNA content heterogeneity in neuroblastoma analyzed by means of image cytometry and its potential significance. Virchows Arch 446: 517-524.
27. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, et al. (2007) Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 81: 114-126.
28. Piqueras M, Navarro S, Canete A, Castel V, Noguera R, (2011) Prognostic value of partial genetic instability in neuroblastoma with
29. Buckley PG, Alcock L, Bryan K, Bray I, Schulte JH, et al. (2010) Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin Cancer Res 16: 2971-2978.
30. Ambros PF, Ambros IM, Kerbl R, Luegmayr A, Rumpler S, et al. (2001) Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas. Med Pediatr Oncol 36: 1-4.
31. Caren H, Erichsen J, Olsson L, Enerback C, Sjoberg RM, et al. (2008) High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics 9: 353.
32. Fix A, Lucchesi C, Ribeiro A, Lequin D, Pierron G, et al. (2008) Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Genes Chromosomes Cancer 47: 819-834.
33. Kryh H, Abrahamsson J, Jegeras E, Sjoberg RM, Devenney I, et al. (2011) MYCN amplicon junctions as tumor-specific targets for minimal residual disease detection in neuroblastoma. Int J Oncol 39: 1063-1071.
34. de Souza DR, Sanabani SS, de Souza AC, Filho Odone V, Epelman S, et al. (2010) Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma. Pediatr Blood Cancer 56: 749-756.
35. Defferrari R, Tonini GP, Conte M, Papio F, Sementa AR, et al. (2007) Concomitant DDX1 and MYCN gain in neuroblastoma. Cancer Lett 256: 56-63.
36. Kaneko S, Ohira M, Nakamura Y, Isogai E, Nakagawara A, et al. (2007) Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma. J Cancer Res Clin Oncol 133: 185-192.
37. De Preter K, Speleman F, Combaret V, Lunec J, Board J, et al. (2005) No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas. J Clin Oncol 23: 3167-3168; author reply 3168-3170.
38. Weber A, Imisch P, Bergmann E, Christiansen H, (2004) Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. J Clin Oncol 22: 2681-2690.
39. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, et al. (2010) Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 16: 4353-4362.
40. Blumrich A, Zapatka M, Brueckner LM, Zheglo D, Schwab M, et al. (2011) The FRA2C common fragile site maps to the borders of MYCN amplicons in neuroblastoma and is associated with gross chromosomal rearrangements in different cancers. Hum Mol Genet 20: 1488-1501.
41. Jeison M, Ash S, Halevy-Berko G, Mardoukh J, Luria D, et al. (2010) 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics. Am J Pathol 176: 2616-2625.
42. McArdle L, McDermott M, Purcell R, Grehan D, O'Meara A, et al. (2004) Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q. Carcinogenesis 25: 1599-1609.
43. Gagos S, Irminger-Finger I, (2005) Chromosome instability in neoplasia: chaotic roots to continuous growth. Int J Biochem Cell Biol 37: 1014-1033.
44. Henrich KO, Bauer T, Schulte J, Ehemann V, Deubzer H, et al. (2011) CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells. Cancer Res 71: 3142-3151.
45. Fieuw A, Kumps C, Schramm A, Pattyn F, Menten B, et al. (2011) Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas. Int J Cancer 130: 2599-2606.
46. Vandesompele J, Michels E, De Preter K, Menten B, Schramm A, et al. (2008) Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics. Int J Cancer 122: 1177-1182.
47. Carr J, Bell E, Pearson AD, Kees UR, Beris H, et al. (2006) Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res 66: 2138-2145.
48. Hoebeeck J, Michels E, Menten B, Van Roy N, Eggert A, et al. (2007) High resolution tiling-path BAC array deletion mapping suggests commonly involved 3p21-p22 tumor suppressor genes in neuroblastoma and more frequent tumors. Int J Cancer 120: 533-538.
49. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, et al. (2001) Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Res 61: 679-686.
50. Villamon E, Piqueras M, Berbegall AP, Tadeo I, Castel V, et al. (2011) Comparative study of MLPA-FISH to determine DNA copy number alterations in neuroblastic tumors. Histol Histopathol 26: 343-350.
51. Assie G, LaFramboise T, Platzer P, Bertherat J, Stratakis CA, et al. (2008) SNP arrays in heterogeneous tissue: highly accurate collection of both germline and somatic genetic information from unpaired single tumor samples. Am J Hum Genet 82: 903-915.